Related Experiment Videos
Probing p53 biological functions through the use of genetically engineered mouse models
Laura D Attardi1, Lawrence A Donehower
1Department of Radiation Oncology and Genetics, Stanford University School of Medicine, CCSR South, CA 94305-5152, USA. attardi@stanford.edu
Mutation Research
|July 26, 2005
Summary
Genetically engineered mouse models with a dysfunctional p53 tumor suppressor gene are crucial for cancer research. These models help understand cancer initiation, aging, and embryogenesis, with future advancements promising clinical relevance.
Area of Science:
- Oncology
- Genetics
- Developmental Biology
Background:
- The p53 tumor suppressor gene is frequently dysfunctional in human cancers.
- Genetically engineered mouse models are essential for studying p53 dysfunction in vivo.
- Various p53 alterations have been generated using transgenic and knock-out technologies.
Purpose of the Study:
- To model the effects of p53 gene dysfunction in a tractable organismal context.
- To investigate the mechanisms of cancer initiation and progression.
- To explore the broader roles of p53 in embryogenesis and aging.
Main Methods:
- Utilizing transgenic and knock-out technologies to create diverse p53 germ line alterations in mice.
- Analyzing spontaneous and carcinogen-induced tumor development in p53 mutant mouse models.
- Investigating the impact of genetic background and additional genetic modifications on tumor phenotypes.
Main Results:
- Many p53 mutant mouse models exhibit increased susceptibility to various tumor types.
- Tumor incidence and spectrum are influenced by factors including genetic background and specific p53 mutations.
- These models provide insights into p53's role beyond cancer, including embryogenesis and aging.
Conclusions:
- p53 mutant mouse models are invaluable tools for understanding cancer biology.
- These models offer unexpected insights into fundamental biological processes regulated by p53.
- Future sophisticated mouse models are expected to yield significant mechanistic and clinical advancements.